Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant ALK-TKI under MRD monitoring in resected ALK-positive NSCLC
ChiCTR2500096642Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of iruplinalkib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
iruplinalkib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500096642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096642.